4.6 Article

The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome

期刊

GENES
卷 12, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/genes12111717

关键词

Wolfram syndrome; Wfs1; Wfs1 knock-out; liraglutide; valproic acid; RAAS; aldosterone; bradykinin; Agtr2; Bdkrb1

资金

  1. Estonian Research Council [PSG471]
  2. European Union through the European Regional Development Fund [2014-2020.4.01.15-0012]
  3. Eye Hope Foundation
  4. CELSA

向作者/读者索取更多资源

Wolfram syndrome (WS) is a rare monogenic neurodegenerative disorder caused by mutations in the gene encoding WFS1 with no current treatment available. Research on a rat model of WS revealed early deviations in the renin-angiotensin-aldosterone system (RAAS) and bradykinin pathway (KKS), as well as the modulatory effect of glucagon-like peptide-1 receptor agonist liraglutide and anti-epileptic drug valproate. These treatments were shown to elevate serum aldosterone and decrease bradykinin levels in WS rats, indicating their potential to modulate these systems.
Wolfram syndrome (WS) 1 is a rare monogenic neurodegenerative disorder caused by mutations in the gene encoding WFS1. Knowledge of the pathophysiology of WS is incomplete and to date, there is no treatment available. Here, we describe early deviations in the renin-angiotensin-aldosterone system (RAAS) and bradykinin pathway (kallikrein kinin system, KKS) observed in a rat model of WS (Wfs1 KO) and the modulative effect of glucagon-like peptide-1 receptor agonist liraglutide (LIR) and anti-epileptic drug valproate (VPA), which have been proven effective in delaying WS progression in WS animal models. We found that the expression of key receptors of the RAAS and KKS, Agtr2 and Bdkrb1, were drastically downregulated both in vitro and in vivo at an early stage in a rat model of WS. Moreover, in Wfs1, KO serum aldosterone levels were substantially decreased and bradykinin levels increased compared to WT animals. Neither treatment nor their combination affected the gene expression levels seen in the Wfs1 KO animals. However, all the treatments elevated serum aldosterone and decreased bradykinin in the Wfs1 KO rats, as well as increasing angiotensin II levels independent of genotype. Altogether, our results indicate that Wfs1 deficiency might disturb the normal functioning of RAAS and KKS and that LIR and VPA have the ability to modulate these systems.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据